Off label use and Galvus


Off Label Use Symptoms and Causes

Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute

Check out the latest treatments for off label use

off label use treatment research studies

Galvus clinical trials, surveys and public health registries

Find Drug Side Effect reports

Galvus Side Effects

Blood Glucose Increased (79)
Malaise (32)
Dizziness (30)
Nausea (30)
Diarrhoea (26)
Blood Pressure Increased (25)
Weight Decreased (22)
Fall (21)
Vomiting (21)
Feeling Abnormal (21)
Diabetes Mellitus Inadequate Control (19)
Fatigue (18)
Pneumonia (18)
Abdominal Pain Upper (17)
Hyperglycaemia (16)
Asthenia (14)
Headache (14)
Hypertension (14)
Hypoglycaemia (13)
Glycosylated Haemoglobin Increased (12)
Diabetes Mellitus (10)
Cerebrovascular Accident (10)
Influenza (10)
Gait Disturbance (10)
Hyperhidrosis (9)
Pain In Extremity (9)
Dyspnoea (8)
Decreased Appetite (7)
Convulsion (7)
Cardiac Disorder (7)
Infarction (7)
Death (7)
Loss Of Consciousness (7)
Pain (7)
Visual Impairment (7)
Myocardial Infarction (7)
Blood Pressure Inadequately Controlled (6)
Blood Glucose Fluctuation (6)
Abdominal Pain (6)
Blood Triglycerides Increased (6)
Blood Cholesterol Increased (6)
Tachycardia (6)
Chest Pain (6)
Cataract (6)
Tremor (6)
Urinary Tract Infection (6)
Weight Increased (6)
Blood Glucose Decreased (5)
Renal Disorder (5)
Anaemia (5)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews


After starting treating with Galvus met 50 / 500mg, my mother diabetis controlled.

Any side effects galvus 5o

Do you kow what age you have too be?

Does galvus has adverse affect? example

Does taking galvus met 500/50 be causing my feeling of not being well? This has been going on for 2 years, but it comes and goes.

Galvus is a breakthrough in antidiabetic market...

Good effects on diabetes. weight reduction -rapid and moderate to excessive hair fall after 3 months of use

Good morning ..i want ask u something,,my fother was take glucovance before 4 days and stigalptin but the dr now change to galvus met and actos,, and today he has nausea is it deal with the medication??

Good results

45 yr old male, went to dentist had a lot of calc buildup, gave me peridex, told me it might be a little strong might need to cut it down or test it first, he gave this to me, I didnt read the label or anything I thought it was just a mouthwash WARNI

Anthony, thank you. I thought I was going nuts. Weight gain would be an understatement. Bloating and gas too. Not sure I want to continue this and I have not been on the 'full' dose --- misread the label and am happy I d

Hi i need information toward somatropin label price?

I had a devastating experience with this drug. I had been using Flexeril for back and neck pain but found it no longer as effective. I asked my doctor if there was something stronger. He prescribed Baclofen. Having not read the label carefully, m

I have been on 20 mg of Cipralex for over 3 years. It does it's job and I do not experience anxiety. In doing your homework, you will see Cipralex is for anxiety which is part of the 'depression' family. One does not label the other. One of the bigg

I have been sick with allergies/asthma/sinusitis for over a week and when I took Mucinex DM I made sure to read the label carefully. My carton said to take 1 every 12 hours and no more than 2 in 24 hours. After taking the first pill it had no effect

I haven't had an abortion induced but the medicine label clearly states to use two forms of protection. If the patient has unprotected sex, that the patient's problem. Every doctor visit my doctor stressed to me how much the medicine could

I may try Lyrica off label for GAD and PD as well as some antidepressive effects I read in journals, articles. Lyrica has been approved for GAD in Europe but hasn't gotten the FDA approval for it here yet. The above poster, Case Report #Self-49

I take Centrum Silver and wanted a label that I could read.

Is a GG 40 with a Sandoz label made in a different laboratory than a GG 40 with a Geneva label? (I know they are both 10 mg of amitriptyline.) Thank you. Appreciate reply as soon as possible.

Off Label Use Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Vildagliptin followed by Sitagliptin;   Drug: Sitagliptin followed by Vildagliptin
Outcome Measures: The hypoglycemic profile of vildagliptin compared to sitagliptin;   Number of hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment.;   Duration of hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment;   grade of severity of hypoglycemia;   Number of severe hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment;   Glucose fluctuations during the day under vildagliptin treatment compared to sitagliptin treatment;   Impact of hypoglycemic events on ECG abnormalities;   Status of pro-inflammatory biomarkers under vildagliptin treatment compared to sitagliptin treatment;   Pro-insulin/C-Peptide ratio during vildagliptin treatment compared to sitagliptin treatment.
2 Recruiting Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
Conditions: Type 1 Diabetes;   Insulin Dependent Diabetes;   Juvenile Onset Diabetes Mellitus;   Autoimmune Diabetes
Intervention: Drug: Vildagliptin
Outcome Measures: Beta cell function;   Immune and inflammatory profile;   Secretion of Glucagon and GLP-1;   Glycemic variability
3 Not yet recruiting Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women
Conditions: 1- Microvascular Function;   2-oxidative Stress;   3-inflammation
Intervention: Drug: Vildagliptin
Outcome Measures: Change from Baseline in microcirculation function at 30 days;   Change from Baseline in endothelial function at 30 days
4 Recruiting Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Condition: Type 2 Diabetes
Interventions: Drug: Vildagliptin;   Drug: Placebo
Outcome Measures: Proportion of patients responding to treatment (HbA1c less than 7%);   Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)
5 Recruiting Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Conditions: Type 2 Diabetes Mellitus;   Hypertension;   Endothelial Dysfunction
Interventions: Drug: Glibenclamide;   Drug: Vildagliptin
Outcome Measures: Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment;   Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment
6 Recruiting Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin;   Drug: Vildagliptin;   Drug: Saxagliptin
Outcome Measures: Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12;   Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12;   Change From Baseline in 2-hour Postprandial Glucose at Week 12;   Change From Baseline in Fasting Insulin at Week 12;   Change From Baseline in Fasting Glucagon at Week 12;   Change From Baseline in 2-hour Postprandial Insulin at Week 12;   Change From Baseline in 2-hour Postprandial Glucagon at Week 12;   Change From Baseline in 2-hour Postprandial Glucagon-like Peptide-1 (GLP-1) at Week 12;   Change From Baseline in Body Weight at Week 12;   Change From Baseline in Fasting Plasma Lipids at Week 12;   The Proportion of Patients Achieving A1C < 7% and Achieving A1C<6.5% at Week12
7 Recruiting VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo to vildagliptin;   Drug: vildagliptin;   Drug: Metformin
Outcome Measures: Rate of loss in glycemic control over time;   Time to initial treatment failure;   Rate of loss in glycemic control in fasting plasma glucose;   Rate of loss in glycemic control in fasting plasma glucose (FPG) during period 2;   Rate of loss of beta cell function from baseline to end of study ( 5 years);   Number patients with adverse events, death and serious adverse events;   Rate of loss in glycemic control in over time;   Rate of change in insulin sensitivity from baseline to end of study (5 years)
8 Recruiting Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Vildagliptin
Outcome Measures: Change from baseline in glycosylated hemoglobin (HbA1c) at week 24;   Change from baseline in glycosylated hemoglobin (HbA1c) at week 12;   Change from baseline in fasting plasma glucose(FPG) at week 12 and 24;   Change from baseline in postprandial plasma glucose(PPG) at week 12 and 24;   Change from baseline in mean amplitude of glycemic excursions (MAGE) by 72-hour continuous glucose monitoring system (CGMS) after 24-week;   Percentage of patients reaching the glycemic goal at week 12 and 24;   Number of patients with adverse events, serious adverse events and hypoglycemic events
9 Recruiting Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
Condition: Type-2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Metformin
Outcome Measures: Mean change of HbA1c from Baseline to Month 12;   Mean change in fasting plasma glucose (FPG) from Baseline to Month 12;   Percentage of patients with HbA1c <7.0%;   Percentage of overall drug compliance in 12 months;   Percentage patients with adverse events, serious adverse events and death as an assessment of overall safety and tolerability
10 Unknown  Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Condition: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Intervention: Drug: Vildagliptin
Outcome Measures: Endothelial Function;   Number and Function of Progenitor Cells
11 Recruiting Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: Vildagliptin;   Drug: Metformin;   Drug: sulfonylurea (SU);   Drug: Basal Insulin
Outcome Measures: Percentage of patients who reported at least one symptomatic hypoglycemic event during the 24 week randomized period in both treatment arms;   Percentage of patients reaching their glycemic target without hypoglycemic events;   Change from baseline in HbA1c to week 24 in both treatment arms;   Change from baseline in body weight in both treatment arms;   Mean daily insulin dose at Week 24;   Percentage of patients with severe and confirmed hypoglycemic events
12 Unknown  Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Condition: Non-Alcoholic Fatty Liver Disease
Interventions: Drug: Galvus (vitagliptin);   Drug: Galvus + vitamin D
Outcome Measure: decrease in histological findings
13 Recruiting Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Conditions: Type 2 Diabetes;   Hypoglycemia
Interventions: Drug: vildagliptin and metformin (combination);   Drug: glimepiride;   Drug: Metformin
Outcome Measures: glycemic variability measured by Mean Amplitude of Average Glucose Excursions (MAGE);   glycemic variability measured by Continuous Overlapping Net Glycemic Action (CONGA);   Percentage of patients who achieve a decrease equal to or greater than 0.3% in value of HbA1c at week 12 of treatment in comparison to HbA1c value at screening visit;   Percentage of reduction achieved in the mean HbA1c at week 12 of treatment in comparison to HbA1c at screening visit;   Degree of correlation between MAGE value and hypoglycemia incidence;   percentage of patients with incidence of hypoglycemia;   Glycemic variability measured by Total Standard Deviation (TSD);   Number of patients with adverse events, serious adverse events and death
14 Recruiting Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hypoglycemic Agents;   Diabetic Blood Glucose Monitoring;   Exercise
Interventions: Drug: MET + Vildagliptin Group;   Drug: MET + Glibenclamide Group
Outcome Measures: Change in Glycemic variability;   Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)
15 Recruiting Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Insulin;   Drug: Placebo
Outcome Measures: Percentage of patients with hyperglycemic events evaluated with CGM;   Number of hypoglycemia and/or hyperglycemia measured by CGM;   Area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day;   Average of insulin units per day administered during the study;   Changes from the baseline in Lipid Profile;   Change from baseline in Body weight;   Change from baseline in Blood pressure (BP),;   Change from baseline in Fasting plasma glucose (FPG),;   Change from baseline in Hemoglobin A1C (HbA1c);   Change from baseline in Creatinine;   Change from baseline in C-peptide;   Changes from baseline in alanine aminotransferase (ALT)/aspartate aminotransferase (AST);   Changes from baseline in Direct bilirubin;   Changes from baseline in Body Mass Index (BMI);   Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin
16 Recruiting Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: LAF237 50 mg;   Drug: Placebo
Outcome Measures: Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups;   Percentage of patients meeting Responder rates in HbA1c;   Change from baseline in Fasting plasma glucose (FPG) at 12 weeks;   Number of participants with hypoglycemia and sever hypoglycemia;   Number of patients with adverse events, serious adverse events and death
17 Unknown  Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Condition: Diabetes Mellitus Type II
Interventions: Drug: Metformin;   Drug: Vildagliptin;   Drug: Glimepiride
Outcome Measures: Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min);   Fasting intact proinsulin levels;   Max postprandial intact proinsulin levels;   Retinal endothelial response to flicker light stimulation;   Mean 24h systolic and diastolic blood pressure;   Erythrocyte deformability;   E-selectin;   Change in body weight;   hsCRP;   HbA1c;   Fasting blood glucose;   Number of hypoglycemic events;   Adverse events;   Drug related adverse events
18 Recruiting Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
Conditions: Type 2 Diabetes Mellitus;   Menopause;   Osteoporosis;   Osteopenia
Interventions: Drug: Vildagliptin;   Drug: Gliclazide MR
Outcome Measures: Markers of bone remodeling;   Bone mineral density of lumbar spine and femur by X-ray absorptiometry;   Glycemic variability;   Calcitonin
19 Recruiting Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
Conditions: Type 2 Diabetes Mellitus;   Ischemic Heart Disease
Interventions: Drug: Metformin plus vildagliptin;   Drug: Metformin only
Outcome Measures: Reduction in serum levels of Interleukin 6 (IL-6);   Improvement in other markers of athero-thrombosis and inflammation:
20 Unknown  The Vascular Effects of Vildagliptin in Insulin Resistant Individuals
Conditions: Insulin Resistance;   Microvascular Disease
Interventions: Drug: Vildagliptin;   Drug: Placebo
Outcome Measures: Capillary pressure;   Macular thickness